Potential biomarkers of long‐term benefit from single‐agent trastuzumab or lapatinib in HER2‐positive metastatic breast cancer

In 2009 a prospective, randomized Phase II trial (NCT00842998) was initiated to evaluate the activity of HER2‐targeting agents without chemotherapy (CT) in HER2‐positive metastatic breast cancer (MBC) patients. The primary tumors of the patients enrolled in this study offered a unique opportunity to...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Mol Oncol
Main Authors: Montemurro, Filippo, Prat, Aleix, Rossi, Valentina, Valabrega, Giorgio, Sperinde, Jeff, Peraldo-Neia, Caterina, Donadio, Michela, Galván, Patricia, Sapino, Anna, Aglietta, Massimo, Baselga, José, Scaltriti, Maurizio
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2013
Teme:
Research Articles
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5528507/
https://ncbi.nlm.nih.gov/pubmed/24075779
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2013.08.013
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki